You are here: Industry Insights > Tris Pharma

News List

Tris Pharma, Neuraxpharm Announce Partnership americanpharmaceuticalreview
December 28, 2020
Tris Pharma and Neuraxpharm Group have entered into an agreement whereby Neuraxpharm received exclusive rights to commercialize Tris' FDA-approved Quillivant XR and Quillichew ER in Europe.
Tris Pharma expands retrieval of potentially dangerous infants' ibuprofen fiercepharma
February 24, 2019
Tris Pharma, which first recalled potentially harmful infants' ibuprofen in December, is adding lots to the recall.
Tris Pharma Issues Recall of Infants' Ibuprofen Concentrated Oral Suspension americanpharmaceuticalreview
December 06, 2018
Tris Pharma, Inc. has voluntarily recalled three (3) lots of Infants' Ibuprofen Concentrated Oral Suspension, USP (NSAID) 50 mg per 1.25 mL, to the retail level.....
Tris Pharma Expands ADHD Portfolio with Acquisition of NextWave Pharmaceuticals pharmafocusasia
December 03, 2018
Tris Pharma, Inc. (Tris), a pharmaceutical company focused on developing innovative technology-based therapeutic products that address unmet patient needs....
Tris Pharma Selects Adents Serialization Software contractpharma
March 31, 2017
Tris Pharma, a specialty pharma company that develops and manufactures OTC and Rx branded and generic products, has chosen Adents software to help assure compliance with upcoming U.S. serialization deadlines.
Tris Pharma Appoints New Chief Commercial Officer for Brand Business americanpharmaceuticalreview
March 13, 2017
Tris Pharma a specialty pharmaceutical company with a portfolio of approved NDAs and late-stage pipeline of innovative technology-based product candidates for the treatment of Attention Deficit Hyperactivity Disorder (ADHD), has appointed Paul Rogers as i